Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.
British life sciences company NetScientific Plc said on June 7 that one of the company’s subsidiaries entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a Covid-19 test.
Moderna is gearing up to halve the dose of the company’s Covid-19 vaccine, the U.S. drugmaker said on June 2, so that it can also be used to combat variants and inoculate children.
Moderna Inc. said on June 1 the company had entered into an agreement with Thermo Fisher Scientific for manufacturing and packaging its Covid-19 vaccine, as the U.S. vaccine maker looks to scale up production.
GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.
One day after Bristol Myers Squibb announced a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Artificial Intelligence (AI)-focused biopharma company Exscientia that could hit $1.2 billion.
Bristol Myers Squibb inked a licensing deal for Agenus’ proprietary bispecific antibody program, AGEN1777, and a second undisclosed target. AGEN1777 is an Fc-enhancement antibody Agenus is developing to target major inhibitory receptors found on T and NK cells that seem to improve anti-tumor activity.
Pfizer reported first-quarter 2021 revenue of $14.6 billion, an impressive 42 percent operational growth. The company’s Covid-19 vaccine revenue accounted for $3.5 billion of the total.
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).